Matinas BioPharma Holdings (MTNB) Assets (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Assets of $5.9 million for Q1 2026, down 51.19% year-over-year from $12.0 million in Q1 2025, and down 18.51% quarter-over-quarter from $7.2 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Assets (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Assets for 14 consecutive years, with $5.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 51.19% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 51.19% YoY), while the FY2025 annual figure was $7.2 million, down 42.98% from the prior year.
- Assets declined to $5.9 million in Q1 2026 per MTNB's latest filing, from $7.2 million in the prior quarter.
- Across five years, Assets topped out at $55.8 million in Q1 2022 and bottomed at $5.9 million in Q1 2026.
- Historically, Assets has averaged $26.5 million across 5 years, with a median of $24.4 million in 2024.
- Annual changes were most pronounced in 2022 — Assets retreated 22.9% — and 2025, when it tumbled 53.11%.
- Matinas BioPharma Holdings' Assets stood at $44.8 million in 2022, then tumbled by 43.99% to $25.1 million in 2023, then plunged by 49.65% to $12.6 million in 2024, then plunged by 42.98% to $7.2 million in 2025, then fell by 18.51% to $5.9 million in 2026.
- Business Quant data shows MTNB's Assets at $5.9 million in Q1 2026, $7.2 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 3.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.41 Mn |
| Mar 31, 2026 | 5.87 Mn |
| Dec 31, 2025 | 7.21 Mn |
| Sep 30, 2025 | 9.70 Mn |
| Jun 30, 2025 | 11.42 Mn |
| Mar 31, 2025 | 12.04 Mn |
| Dec 31, 2024 | 12.64 Mn |
| Sep 30, 2024 | 20.58 Mn |
| Jun 30, 2024 | 24.37 Mn |
| Mar 31, 2024 | 19.61 Mn |
| Dec 31, 2023 | 25.10 Mn |
| Sep 30, 2023 | 29.79 Mn |
| Jun 30, 2023 | 34.03 Mn |
| Mar 31, 2023 | 38.26 Mn |
| Dec 31, 2022 | 44.82 Mn |
| Sep 30, 2022 | 47.55 Mn |
| Jun 30, 2022 | 52.42 Mn |
| Mar 31, 2022 | 55.78 Mn |
| Dec 31, 2021 | 61.33 Mn |
| Sep 30, 2021 | 66.98 Mn |